Show simple item record

dc.contributor.authorStavropoulos-Kalinoglou, A
dc.contributor.authorMetsios, GS
dc.contributor.authorPanoulas, VF
dc.contributor.authorNightingale, P
dc.contributor.authorKoutedakis, Y
dc.contributor.authorKitas, GD
dc.date.accessioned2021-01-25T12:46:18Z
dc.date.available2021-01-25T12:46:18Z
dc.date.issued2012-07-05
dc.identifier.citationStavropoulos-Kalinoglou, A., Metsios, G.S., Panoulas, V.F. et al. (2012) Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis . Arthritis Research & Therapy, 14, R160 (2012). https://doi.org/10.1186/ar3900en
dc.identifier.issn1478-6362en
dc.identifier.pmid22765047 (pubmed)
dc.identifier.doi10.1186/ar3900en
dc.identifier.urihttp://hdl.handle.net/2436/623894
dc.description© 2012 The Authors. Published by BMC. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.1186/ar3900en
dc.description.abstractIntroduction: Insulin resistance (IR), a risk factor for the development of cardiovascular disease, is common among patients with rheumatoid arthritis (RA). Inflammation, and especially tumour necrosis factor alpha (TNFα), has been associated with IR, and the administration of anti-TNFα agents is suggested to improve insulin sensitivity. However obesity, a potent contributor to IR, may limit the beneficial effects of anti-TNFα medication on IR. The aim of this study is to compare the effects of anti-TNFα therapy on IR between normal-weight and obese patients with RA.Methods: Patients who were normal-weight with IR (N+IR) or obese with IR (O+IR) and had embarked on anti-TNFα treatment, participated. Assessments included body mass index (BMI), insulin sensitivity (Homeostasis Model Assessment of insulin resistance, HOMA and the Quantitative Insulin sensitivity Check Index, QUICKI), and RA disease characteristics before and following six months of anti-TNFα treatment. Their results were compared to matched (for age, gender, BMI, disease duration and smoking status) normal-weight patients without IR (N-IR) and obese without IR (N-IR), respectively. In total, 32 patients were assessed for this study, with 8 in each group.Results: Following six months of treatment, disease activity was significantly reduced in all groups (P < 0.05) to a similar extent (P for differences between groups > 0.05 in all cases). In the total population, changes in HOMA (mean reduction at 6 m = -0.2 ± 0.1; P = 0.088) and QUICKI (mean increase at 6 m = 0.03 ± 0.022; P = 0.092) after treatment were not statistically significant, though a trend towards improvement was observed. However, N+IR patients showed a significant decrease in HOMA (mean reduction at 6 m = -0.54 ± 0.2; P = 0.002) and increase in QUICKI (mean increase at 6 m = 0.046 ± 0.02; P = 0.011). These changes were significantly different compared to the other groups (P < 0.05 in all cases). Multivariable analyses showed that the change in Erythrocyte Sedimentation Rate (ESR), and the change in C-Reactive Protein (CRP) associated with the improvement in HOMA (ESR: F 1-7 = 5.143, P = 0.019; CRP: F 1-7 = 3.122, P = 0.022) and QUICKI (ESR: F 1-7 = 3.814, P = 0.021; CRP: F 1-7 = 2.67; P = 0.041) only in the N+IR group.Conclusions: Anti-TNFα therapy, through controlling inflammation, seems to improve insulin sensitivity in normal-weight RA patients with insulin resistance, but is not sufficient to achieving the same beneficial effect in obese RA patients with insulin resistance. © 2012 Stavropoulos-Kalinoglou et al.; licensee BioMed Central Ltd.en
dc.description.sponsorshipThis study was funded by the Dudley Hospitals NHS Foundation Trust R&D Directorate. The Department of Rheumatology, Dudley Hospitals NHS Foundation Trust, has an infrastructure support grant from Arthritis Research UK (number: 17682).en
dc.formatapplication/pdfen
dc.languageeng
dc.language.isoenen
dc.publisherSpringer Science and Business Media LLCen
dc.relation.urlhttps://arthritis-research.biomedcentral.com/articles/10.1186/ar3900en
dc.rightsLicence for published version: Creative Commons Attribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectrheumatoid arthritisen
dc.subjectinsulin resistenceen
dc.subjectrheumatoid arthritis patienten
dc.subjectimprove insulin sensitivityen
dc.subjectbaseline body mass indexen
dc.subject.meshHumans
dc.subject.meshArthritis, Rheumatoid
dc.subject.meshInsulin Resistance
dc.subject.meshObesity
dc.subject.meshBody Weight
dc.subject.meshTumor Necrosis Factor-alpha
dc.subject.meshAntirheumatic Agents
dc.subject.meshAged
dc.subject.meshMiddle Aged
dc.subject.meshFemale
dc.subject.meshMale
dc.titleAnti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritisen
dc.typeJournal articleen
dc.identifier.eissn1478-6362
dc.identifier.journalArthritis Research and Therapyen
dc.date.updated2021-01-24T19:53:22Z
pubs.place-of-publicationEngland
dc.date.accepted2012-07-05
rioxxterms.funderVersus Arthritisen
rioxxterms.identifier.project17682en
rioxxterms.versionVoRen
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2021-01-25en
dc.source.volume14
dc.source.issue4
dc.source.beginpageR160
dc.description.versionPublished version
refterms.dateFCD2021-01-25T12:46:05Z
refterms.versionFCDVoR
refterms.dateFOA2021-01-25T12:46:19Z


Files in this item

Thumbnail
Name:
Anti-tumour necrosis factor alpha ...
Size:
422.6Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Licence for published version: Creative Commons Attribution 4.0 International
Except where otherwise noted, this item's license is described as Licence for published version: Creative Commons Attribution 4.0 International